Navigation Links
Results of Phase II Study of Boehringer Ingelheim's Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
Date:5/21/2012

SAN FRANCISCO, May 21, 2012 /PRNewswire/ -- Data from a Phase II trial of olodaterol presented today at the 2012 Annual International Conference of the American Thoracic Society (ATS 2012) compared the efficacy of once-daily (QD) versus twice-daily (BID) olodaterol, a long-acting beta2-agonist (LABA) that Boehringer Ingelheim is evaluating as a possible maintenance treatment for chronic obstructive pulmonary disease (COPD), delivered via the Respimat® Inhaler. In this Phase II randomized, double-blind, cross-over study, olodaterol administered QD as 5 micrograms or 10 micrograms provided a significant and identical increase in the lung function parameter FEV1 over a 24-hour period. This data completes the olodaterol monotherapy Phase II clinical trial program in patients with COPD.

"In this Phase II study, olodaterol administered once daily provided significant bronchodilation over a complete 24-hour period," said Professor Guy Joos, Head of the Department of Respiratory Diseases at Ghent University Hospital, Belgium, and the coordinating investigator for the trial. "These data are encouraging, and set the stage for olodaterol to be further investigated in Phase III studies in patients with COPD."

Results of the study found olodaterol 5 microgram QD provided significant improvement in lung function as measured by FEV1 AUC(0-12) versus twice-daily olodaterol 2 microgram, while twice-daily dosing of olodaterol 5 microgram had a better FEV1 AUC(0-12) profile versus once-daily olodaterol 10 microgram.  There were no safety or tolerability concerns seen in the study, with no relationship between total daily dose to the overall incidence of adverse events. These results were comparable to previous Phase II studies.

"These trial results and the completion of the olodaterol monotherapy Phase II clinical trial program underscore the Company's focus on advancing respiratory research and treatment,"
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Study Results of Novocures NovoTTF™ Pivotal Phase 3 Trial Published in European Journal of Cancer
2. InspireMD Announces Positive 3-Year Results from Extended MAGICAL trial
3. ShangPharma Announces First Quarter 2012 Results
4. Inrad Optics, Inc. Announces Financial Results For First Quarter 2012
5. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
6. Patient Safety Technologies Reports First Quarter 2012 Results
7. Nephros Reports First Quarter 2012 Financial Results
8. MedClean Technologies Announces 2011 Results
9. Nile Therapeutics Reports 2012 First Quarter Financial Results
10. OphthaliX Reports First Quarter 2012 Financial Results
11. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014 ... used to inflate sales of brand drugs among ... D,  according to a new report  from ... Office of the Inspector General (OIG). Federal anti-kickback laws ... of goods that are subsidized by the federal ...
(Date:9/19/2014)... DUBLIN , September 19, 2014 /PRNewswire/ ... http://www.researchandmarkets.com/research/s6g5wm/global ) has announced the addition of ... report to their offering. ... devices have been broadly classified into wide ... are used for the treatment of different ...
(Date:9/19/2014)... CHICAGO , Sept. 19, 2014  4WEB Medical ... of 3D-printed foot and ankle osteotomy implants on ... and Ankle Society annual meeting in Chicago ... for all of a surgeon,s osteotomy needs with 74 size ... wedge systems had smaller offerings of only 15 to 18 ...
Breaking Medicine Technology:PCMA: New OIG Report Cites Drug Manufacturer "Copay Coupon" Use in Medicare Part D 2Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 2Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 34WEB Medical Unveils 3D-Printed Osteotomy Truss System 2
... Alcoa (NYSE: AA ) today announced a ... CDXS ) and CO2 Solution Inc. (TSX-V: CST), focused ... neutralizing the material to create a commercially viable product. ... world,s leading aluminum producer and will be funded by Alcoa ...
... a new market research report is available in its catalogue: ... http://www.reportlinker.com/p0470752/World-In-Vitro-Diagnostics-Market.html Global ... The Freedonia Group projects world demand for in vitro diagnostic ... in 2014. Based on the advanced nature of medical delivery ...
Cached Medicine Technology:Alcoa Unveils Partnership for Carbon Capture Technology Pilot Test Designed to Turn Emissions Into Beneficial Commercial Products 2Alcoa Unveils Partnership for Carbon Capture Technology Pilot Test Designed to Turn Emissions Into Beneficial Commercial Products 3Alcoa Unveils Partnership for Carbon Capture Technology Pilot Test Designed to Turn Emissions Into Beneficial Commercial Products 4Alcoa Unveils Partnership for Carbon Capture Technology Pilot Test Designed to Turn Emissions Into Beneficial Commercial Products 5Reportlinker Adds World In Vitro Diagnostics Market 2Reportlinker Adds World In Vitro Diagnostics Market 3Reportlinker Adds World In Vitro Diagnostics Market 4Reportlinker Adds World In Vitro Diagnostics Market 5Reportlinker Adds World In Vitro Diagnostics Market 6Reportlinker Adds World In Vitro Diagnostics Market 7Reportlinker Adds World In Vitro Diagnostics Market 8Reportlinker Adds World In Vitro Diagnostics Market 9
(Date:9/20/2014)... (PRWEB) September 20, 2014 Final Cut ... announced the release of the Information theme for FCPX filmmakers. ... use to describe the Information theme,” says Christina Austin, CEO ... to look so professional.” , Information features easy to use ... parameters of the environment. Change the background color, color of ...
(Date:9/20/2014)... MarijuanaDoctors.com recently returned to New ... PAIN Week conference that was held at the ... Las Vegas from September 2nd to September 6th. ... in the hopes of educating physicians in regards ... tool to treat chronic Pain, MarijuanaDoctors.com accomplished goals ...
(Date:9/19/2014)... 19, 2014 “Copay coupons,” a drug ... brand drugs among patients with prescription drug coverage, may ... a new report from the Department of Health ... Federal anti-kickback laws prohibit suppliers from offering side-payments to ... federal government. , The report highlights that two recent ...
(Date:9/19/2014)... 2014 (HealthDay News) -- As kids transition from elementary ... cyberbullies, according to a recent study. But ... 8 found that verbal and physical bullying declines as ... intervention and prevention strategies must address all types of ... and girls, the researchers said. The study was published ...
(Date:9/19/2014)... with The Melanoma Genetics Consortium, GenoMEL, an international research ... Journal of the National Cancer Institute that proves ... the first time, we have established that the genes ... in the risk of developing melanoma," said lead author ... at the University of Leeds (UK). , Telomeres ...
Breaking Medicine News(10 mins):Health News:Today Pixel Film Studios Announced the Release of the Information Theme for Final Cut Pro X 2Health News:MarijuanaDoctors.com Experiences Unprecedented Support and Growth at Pain Week 2014 2Health News:PCMA: New OIG Report Cites Drug Manufacturer“Copay Coupon” Use in Medicare Part D 2Health News: Cyberbullying Seems to Ramp Up in Middle School 2Health News:Melanoma risk found to have genetic determinant 2
... Customers to Contribute $5 to Support,the American Red ... The Wireless Foundation,and the American Red Cross ... can make a charitable donation to the Red ... program. Here,s how it works:,Subscribers of participating wireless ...
... launch a new series in the ... field of cancer research., ... exclusive XM Satellite broadcast to health care,professionals of Stand Up To ... ReachMD XM 157 joins the,major TV networks of ABC, CBS and ...
... Entertainment to State,s Largest Hospice ... ... LodgeNet,Healthcare, a division of LodgeNet Interactive Corporation (Nasdaq: LNET ),today ... Patient Television System to the state,s first,hospice program, St. Francis Hospice ...
... reluctance to prescribe antidepressants, study suggests , , TUESDAY, Sept. 2 ... on the rise after a 15-year decline, and the trend ... a new study suggests. , Researchers thought a spike in ... the new study found the increase in suicides continued during ...
... Chapel Hill researchers have demonstrated that a drug called ... and hospital admissions in children with acute gastroenteritis. , ... that causes vomiting and diarrhea. It is often popularly ... in children during the winter months. , "Children under ...
... says , , TUESDAY, Sept. 2 (HealthDay News) -- ... and cancer risk, but it also suggests that ... The results of a small study published recently ... of developing cancer. In that study, called SEAS, ...
Cached Medicine News:Health News:Wireless Subscribers Can Text 2HELP the American Red Cross 2Health News:Wireless Subscribers Can Text 2HELP the American Red Cross 3Health News:ReachMD XM 157 to Present Stand Up To Cancer Special as the Only Live Simulcast on XM Satellite Radio for Health Care Professionals 2Health News:ReachMD XM 157 to Present Stand Up To Cancer Special as the Only Live Simulcast on XM Satellite Radio for Health Care Professionals 3Health News:LodgeNet Healthcare Expands Into Hawaii Through Agreement With St. Francis Hospice 2Health News:LodgeNet Healthcare Expands Into Hawaii Through Agreement With St. Francis Hospice 3Health News:Youth Suicides Continue to Rise in U.S. 2Health News:Youth Suicides Continue to Rise in U.S. 3Health News:Ondansetron reduces vomiting, hospital admissions in children with gastroenteritis 2Health News:No Definitive Link Seen Between Vytorin and Cancer 2Health News:No Definitive Link Seen Between Vytorin and Cancer 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: